Addex Regained Global Rights to GABAB Portfolio
The biotech firm will now independently manage its chronic cough development program and seek new partnerships.
Updated on Sept. 25, 2026 in Healthcare
Live Poll
Does the consolidation of pharmaceutical research companies benefit the development of new treatments?
Addex Therapeutics has regained full global ownership of its GABAB positive allosteric modulator assets following a terminated research collaboration with Indivior UK Limited. The move allows Addex to independently advance its pipeline, including candidates targeting chronic cough.
Why it matters
The change follows a strategic rationalization of research and development activities at Indivior, which is planning a merger with Supernus Pharmaceuticals. Addex must now decide how to fund and resource the further development of these assets through new partnerships or internal efforts.
Addex Therapeutics maintains a 20% equity interest in Neurosterix US Holdings LLC as it reclaims its GABAB PAM portfolio. The company now has full autonomy to pursue indications beyond the scope of its prior arrangement with Indivior.
The players
Addex Therapeutics
A Geneva-based pharmaceutical company focused on the discovery and development of small-molecule, allosteric modulators.
Indivior UK Limited
A global pharmaceutical company specializing in treatments for addiction and serious mental health conditions.
Supernus Pharmaceuticals, Inc.
A specialty pharmaceutical company that is currently planning a merger with Indivior.
Neurosterix US Holdings LLC
A specialized research entity in which Addex Therapeutics maintains a 20% equity stake.
The details
The termination of the research collaboration grants Addex complete control over its development candidate for chronic cough. By regaining global rights, Addex is no longer restricted by Indivior's internal R&D priorities or oversight. The firm now intends to evaluate strategic options to continue advancing these programs, which may include sourcing new pharmaceutical partners or accelerating internal development timelines.
Timeline
September 25, 2026: Addex announced the official return of the GABAB rights.
Market Landscape
This asset reclamation follows the pattern of R&D rationalization seen in industry consolidation, where larger entities divest programs to streamline operations for an upcoming merger. The shift highlights how pharmaceutical deals often trigger the return of secondary portfolio assets to smaller biotech originators.
Operators in the biotech sector should track how Addex leverages its newly regained assets to influence future partnership valuations. Firms should monitor upcoming strategic updates from Addex to determine if these programs become available for licensing or co-development.
The takeaway
When larger partners consolidate and exit specific therapeutic areas, smaller firms must rapidly pivot to secure the value of their returned intellectual property. Operators should monitor the progress of the chronic cough program as a signal for the company's ability to attract new development capital.
Further reading
For more on industry asset shifts, visit the Healthcare section.
More information
For more information on the company's asset status, visit the Addex Therapeutics corporate website.
Live Poll
Does the consolidation of pharmaceutical research companies benefit the development of new treatments?
